

A Service of



Leibniz-Informationszentrum Wirtschaft Leibniz Information Centre for Economics

Díaz, Lina; Villarreal, Deborah Martínez; Márquez, Karina; Scartascini, Carlos G.

Working Paper Combating vaccine hesitancy: The case of HPV vaccination

IDB Working Paper Series, No. IDB-WP-1673

Provided in Cooperation with: Inter-American Development Bank (IDB), Washington, DC

Suggested Citation: Díaz, Lina; Villarreal, Deborah Martínez; Márquez, Karina; Scartascini, Carlos G. (2025) : Combating vaccine hesitancy: The case of HPV vaccination, IDB Working Paper Series, No. IDB-WP-1673, Inter-American Development Bank (IDB), Washington, DC, https://doi.org/10.18235/0013410

This Version is available at: https://hdl.handle.net/10419/315932

Standard-Nutzungsbedingungen:

Die Dokumente auf EconStor dürfen zu eigenen wissenschaftlichen Zwecken und zum Privatgebrauch gespeichert und kopiert werden.

Sie dürfen die Dokumente nicht für öffentliche oder kommerzielle Zwecke vervielfältigen, öffentlich ausstellen, öffentlich zugänglich machen, vertreiben oder anderweitig nutzen.

Sofern die Verfasser die Dokumente unter Open-Content-Lizenzen (insbesondere CC-Lizenzen) zur Verfügung gestellt haben sollten, gelten abweichend von diesen Nutzungsbedingungen die in der dort genannten Lizenz gewährten Nutzungsrechte.



WWW.ECONSTOR.EU

https://creativecommons.org/licenses/by/3.0/igo/

Terms of use:

Documents in EconStor may be saved and copied for your personal and scholarly purposes.

You are not to copy documents for public or commercial purposes, to exhibit the documents publicly, to make them publicly available on the internet, or to distribute or otherwise use the documents in public.

If the documents have been made available under an Open Content Licence (especially Creative Commons Licences), you may exercise further usage rights as specified in the indicated licence.



WORKING PAPER N° IDB-WP-1673

Combating Vaccine Hesitancy:

The Case of HPV Vaccination

Lina Díaz Deborah Martínez Villarreal Karina Márquez Carlos Scartascini

Inter-American Development Bank Department of Research and Chief Economist

February 2025



Combating Vaccine Hesitancy:

The Case of HPV Vaccination

Lina Díaz* Deborah Martínez Villarreal** Karina Márquez* Carlos Scartascini*

* Inter-American Development Bank** American Cancer Society

Inter-American Development Bank Department of Research and Chief Economist

February 2025



Cataloging-in-Publication data provided by the Inter-American Development Bank Felipe Herrera Library

Combating vaccine hesitancy: the case of HPV vaccination / Lina Diaz, Deborah Martinez, Karina Marquez, Carlos Scartascini. p. cm. — (IDB Working Paper Series; 1673) Includes bibliographical references. 1. Papillomaviruses-Vaccination-Colombia. 2. Health behavior-Colombia. 3. Economics-Psychological aspect-Colombia. 4. Human behavior. I. Diaz, Lina M. II. Martínez V., Deborah. III. Marquez, Karina. IV. Scartascini, Carlos G. V. Inter-American Development Bank. Department of Research and Chief Economist. VI. Series. IDB-WP-1673

http://www.iadb.org

Copyright © 2025 Inter-American Development Bank ("IDB"). This work is subject to a Creative Commons license CC BY 3.0 IGO (<u>https://creativecommons.org/licenses/by/3.0/igo/legalcode</u>). The terms and conditions indicated in the URL link must be met and the respective recognition must be granted to the IDB.

Further to section 8 of the above license, any mediation relating to disputes arising under such license shall be conducted in accordance with the WIPO Mediation Rules. Any dispute related to the use of the works of the IDB that cannot be settled amicably shall be submitted to arbitration pursuant to the United Nations Commission on International Trade Law (UNCITRAL) rules. The use of the IDB's name for any purpose other than for attribution, and the use of IDB's logo shall be subject to a separate written license agreement between the IDB and the user and is not authorized as part of this license.

Note that the URL link includes terms and conditions that are an integral part of this license.

The opinions expressed in this work are those of the authors and do not necessarily reflect the views of the Inter-American Development Bank, its Board of Directors, or the countries they represent.



Abstract

Cervical cancer, primarily caused by persistent Human Papillomavirus (HPV) infection, remains one of the leading causes of cancer-related deaths among women in developing countries. Although HPV vaccines are widely available in these regions, vaccine uptake remains persistently low. To address behavioral barriers contributing to this low demand, we evaluated the effectiveness of a behaviorally informed SMS campaign targeting parents in Cali, Colombia. Our study included 15,231 parents, who were randomized into six groups: control, placebo, and four behaviorally informed treatment groups, forming a large-scale study of text-based nudges. Participants received tailored messages over eight weeks. The intervention yielded significant increases in vaccination rates, with improvements ranging from 34% to 55%. Furthermore, the economic analysis demonstrated that the intervention generated between USD 3.6 and USD 5.75 in economic benefits for every dollar spent, primarily due to prevented deaths. These findings underscore the potential of behavioral interventions in enhancing HPV vaccination rates among parents and emphasize the cost-effectiveness and relative success of each intervention strategy. This study provides actionable insights for public health officials to de sign targeted strategies that address vaccination disparities and promote preventive healthcare practices.

JEL classifications: D01, I12 **Keywords:** Vaccination, HPV vaccine, Behavioral science

The research agenda this paper is part of would not have been possible without the support of the American Cancer Society, Liga Colombiana contra el Cáncer, SURA, the Governments of the Cities of Bogotá and Cali, the Colombian Ministry of Health, and the joint work with Meenu Anand and Stanislao Maldonado. This research was financed by the Inter-American Development Bank (IDB) and the American Cancer Society (ACS). ACS and IDB management had no involvement in the study design, analysis, or interpretation of the data, in the writing of the report, or in the decision to submit the article for publication. None of the authors have a conflict of interest to disclose. The opinions expressed here are those of the authors and do not necessarily reflect the views of the Inter-American Development Bank, its Board of Directors, or the countries they represent. Data collection was IRB-approved by Innovations for Poverty Action IRB Board (IRB Protocol No.4275)

1 Introduction

Human papillomavirus (HPV) infection is the most prevalent sexually transmitted disease (STD) in the United States and is very common worldwide (CDC, 2024; WHO, 2017). This infection causes around 730,000 cancer cases annually, and is responsible for 100% of cervical cancer cases (ACS, 2024; Amadane et al., 2019; Ebrahimi et al., 2023). This fourth most common cancer among women globally causes about one percent of all female deaths worldwide, with over 80% of these deaths occurring in developing countries (Agosti and Goldie, 2007; WHO, 2024a).¹

HPV vaccination is a highly effective strategy for preventing cervical cancer. Eliminating cervical cancer requires achieving 90% HPV vaccination coverage (WHO, 2023).² Despite significant efforts to promote vaccination, including its inclusion in national immunization programs and providing free access, a considerable segment of the population remains unvaccinated (WHO, 2024b). This reluctance may stem from a lack of awareness and knowledge about HPV-related diseases and insufficient information regarding the vaccine's benefits and long-term safety (Aggarwal et al., 2024; Cordoba-Sanchez et al., 2022; Brabin et al., 2008). The relationship between HPV and sexuality may be a contributing factor to vaccine hesitancy (Cordoba-Sanchez et al., 2022; Zimet et al., 2008). Mistrust about the safety of the vaccine and biased perceptions about the social norm have also contributed to the low demand.

Colombia stands out due to its high vaccine availability but low demand. The government introduced the HPV vaccine into the Colombian National Immunization Program (CNIP) Schedule in 2012, making it available free of charge for girls aged 9 to 17 (since 2012) and boys (since 2023). Citizens can receive the vaccine at any vaccination center, regardless of their health provider or insurer. As a result, Colombia became a leader in HPV vaccination coverage in Latin America by 2012, achieving a 95% vaccination rate for the targeted population within two years of including the HPV vaccine in their national program (Castro, 2018; Cordoba-Sanchez et al., 2022). The vaccine was widely administered in schools and vaccination centers, leading to nearly universal vaccination rates for the targeted group of 9-year-old girls.

Unfortunately, in 2014, 15 women from Carmen de Bolívar, a city in Colombia, were

¹HPV is also associated with other types of anogenital cancers, head and neck cancers, and genital warts in both men and women.

 $^{^{2}}$ The Center for Disease Control and Prevention recommends a two-dose schedule with a 6-month interval between doses and endorses receiving the first dose before 15 years old (CDC, 2019).

admitted to the local hospital's emergency department with symptoms such as abdominal pain, headaches, dizziness, and fainting upon admission (Castro, 2018). Despite several subsequent safety studies finding no association between the symptoms and HPV vaccination, extensive media attention during this period precipitated a pervasive surge in vaccine hesitancy across the nation (Cordoba-Sanchez et al., 2022). Consequently, the immunization rate fell to 14% (1 dose) and 5% (2 doses) in 2016 (Castro, 2018; Castro et al., 2020). While it has been recovering, levels remain low.

By 2023, several factors worked against vaccination: negative attitudes towards vaccination, withdrawal of HPV from the set of vaccines that can be provided at school, and a reduction in the share of doctors recommending the vaccine for fear of parent retaliation. These factors contributed to an increase in the individual cost of getting the vaccine (both physical and cognitive) and less information available to the population regarding the vaccine.

Behavioral interventions using tailored messages can effectively nudge individuals towards positive health decisions, including vaccine uptake (Dai et al., 2021; Milkman et al., 2021b, 2022; WHO and WB, 2024). However, the effectiveness of such interventions has been underexplored in developing countries. Moreover, increasing HPV vaccination in scenarios where a drastic event led to a spike in hesitancy, higher take-up costs, and lower information remains a gap in the literature.

This study aims to fill the gap in HPV vaccination take-up in a high-hesitancy scenario. Factors contributing to this hesitancy include diminished public confidence in the HPV vaccine, hindered promotion and provision of the vaccine by government authorities, a lack of endorsement and support from medical professionals, and the media's dissemination of sensationalized misinformation. To tackle these issues, a behaviorally informed intervention was conducted in Cali, Colombia.

The intervention was conducted in collaboration with the Secretariat of Health of Cali, which provided us with access to the client database of the private health insurance company SURA³. Approximately 15,000 parents participated in the study and were randomly assigned to six equal groups: a control group, a placebo group, and four treatment groups that received an informational treatment, a social norms treatment, a trust treatment, and a framing treatment. Testing multiple treatments associated with identified behavioral barriers allows for more tailored recommendations to policymakers and a better understanding of the

 $^{^{3}}$ The database provided was restricted to individuals with daughters eligible for the free HPV vaccination, and the information was limited to this specific vaccine.

potential relevance of these barriers (Duckworth and Milkman, 2022; Milkman et al., 2021a).

Results indicate that the messages were effective in increasing vaccination rates. The informational SMS group saw a 2.8 percentage point (pp) increase, equivalent to a 48.3% rise. The social norms SMS group experienced a 2 pp increase, equivalent to a 34.5% rise. The trust SMS group demonstrated a 3.2 pp increase, equivalent to a 55.2% rise. Lastly, the framing SMS group displayed a 2.7 pp increase, equivalent to a 46.6% rise in the vaccination rate. Increasing confidence in the vaccines and providing information from reliable sources appear to be more effective than the other treatment arms, although the differences among treatments are not statistically significant.

These findings, coupled with the intervention's high cost-effectiveness, demonstrate that behavioral interventions can significantly increase vaccination rates, even in challenging circumstances marked by high vaccine hesitancy. In contrast, efforts lacking a behavioral approach have often failed to address persistently low HPV vaccination rates. For instance, in Japan, HPV vaccine coverage among girls aged 12 to 16 initially reached 70%. However, following widespread media coverage of unrelated adverse events, the government suspended proactive recommendations in 2013. This decision led to a dramatic decline in HPV vaccination rates, dropping to less than 1% and remaining at that level (Simms et al., 2020). Although the government resumed proactive recommendations after an eight-year hiatus, vaccination rates have yet to recover to their previous levels.

Given the importance of this issue in Latin America, the Caribbean, and other developing regions, alongside the growing global challenge of vaccine hesitancy, this paper lays a foundation for future research aimed at increasing HPV and other vaccination rates. Future studies could explore the relative effectiveness of various intervention types, including text message campaigns, as examined here, as well as provider-based and practice-based communication strategies (Austin and Morgan, 2019; Cates et al., 2018).

2 The Intervention

2.1 Determinants of Vaccination Demand: Analytical Framework

Consider a very simple model to understand why people may decide to vaccinate or not.⁴ For simplicity, assume that decisions occur in two periods. In the first period, the individual decides whether to vaccinate (e.g., during the teenage years). In the second period, they

⁴Model adapted from Tsutsui et al. (2012).

suffer the potential consequences (e.g., adulthood). We abstract from the fact that parents are deciding for their children in the case of HPV.

We denote the probability of contracting the virus as p, the effectiveness of the HPV vaccine as α , and the damage of contracting the virus as D. Thus, the damage from contracting the virus is reduced to $(1 - \alpha)D$, where α is assumed to take a value between zero and one (the more effective the vaccine, the lower the damage.)

The cost of vaccination, denoted as C(F, opp, psych, S), consists of the inoculation fee or physical cost of vaccination F, opportunity costs opp, psychological costs psych, and perceived side effects of vaccination S. We assume these costs are borne at the time of vaccination.

Decision to be vaccinated: The individual's utility is defined over consumption in two periods, denoted as c_1 and c_2 . In period 1, the individual decides whether to take the vaccine. In period 2, they may or may not be infected by the virus. The expected utility if vaccinated is:

$$u(c_1 - C(F, opp, psych, S)) + \delta \left[(1 - p)u(c_2) + p \cdot u(c_2 - (1 - \alpha)D) \right]$$
(1)

Utility in period 1 equals the level of consumption minus the cost of vaccination. In period 2, the individual faces the lottery of not being infected and enjoying full consumption or being infected with reduced damage due to the vaccine's effectiveness. The expected utility if not vaccinated is:

$$u(c_1) + \delta \left[(1-p)u(c_2) + p \cdot u(c_2 - D) \right]$$
(2)

Here, the individual does not incur vaccination costs in period 1 but accepts the full cost of the illness if infected.

The implications of the model are straightforward:

- Effectiveness of the vaccine (α): As perceptions regarding α increase (i.e., people believe the vaccine is effective), vaccination becomes more attractive, increasing the likelihood of vaccination.
- Probability of contracting the virus (p): As perceptions about contracting the virus p increase, the relevance of vaccination to mitigate risks and damages rises, thereby increasing the probability of vaccination.
- Cost of vaccination (F, opp, psych, S): Higher vaccination costs make vaccination less attractive, decreasing the probability of vaccination.

- Damage from HPV infection (D): Greater perceived damage from HPV infection increases the benefit of vaccination, making vaccination more likely.
- Time preference (δ) . Higher δ increases the weight individuals put on future utility and, therefore, the valuation of potential future harm. This increases the probability of vaccination.

Is this model useful for explaining the drop in vaccination rates in Colombia? The discontinuation of school-based vaccination programs likely increased the perceived cost, F, as people might now believe the vaccine is no longer free. It also likely increased *opp*, as obtaining the vaccine now requires more time and effort. Additionally, thinking that others are not vaccinating their children may have increased the psychological costs of vaccination. Media coverage of potential adverse effects may have elevated the cost S.

Furthermore, the government's cessation of communication campaigns and the lack of proactive recommendations by doctors may have reduced public perceptions of the vaccine's effectiveness (α), the probability of contracting the virus (p), and the potential damage from HPV infection (D).

Next, we evaluate whether the data support these hypotheses.

2.2 Determinants of Vaccination Demand: Diagnostic

A qualitative analysis was conducted to understand parents' decision-making process regarding HPV vaccination and determine key behavioral barriers. Several hypotheses were developed to explain the lack of vaccination, aiming to identify potential bottlenecks. This process was supported by a process-mapping exercise that systematically outlined the key decisions and actions a parent in Cali must take to successfully vaccinate their child against HPV^5 .

Based on the results of this analysis, an interview guide was designed to directly test these hypotheses by exploring how parents experienced each step of the vaccination journey⁶. Participant recruitment was conducted by administrative health professionals using a nonrandom, convenience sampling approach to capture diverse perspectives on HPV vaccine uptake⁷. The final sample consisted of 14 eligible parents of unvaccinated daughters who

⁵The process map was built based on a literature review, local partner insights, and expert consultations, ensuring it reflected both global evidence and local realities.

⁶Open-ended questions allowed participants to describe their decision-making processes, challenges, and sources of influence, providing qualitative evidence on the validity of our hypotheses.

⁷Parents interviewed belonged to all the geographical areas defined by the Immunization Program (centro, ladera, norte, oriente, sur oriente) to ensure a comprehensive understanding of community viewpoints.

were interviewed to explore their knowledge and awareness of vaccines—particularly HPV vaccines and cervical cancer—, the health services their daughters received, and whether their doctor had recommended the HPV vaccine. Parents were also explicitly asked about their reasons for not vaccinating their daughters and their perceptions of the vaccine⁸.

The information gathered from the interviews was systematically reviewed to evaluate whether each hypothesis was supported by the data. Hypotheses were categorized as *confirmed* if responses strongly aligned with the predicted barrier, *refined* if findings suggested additional nuances or modifications to the original assumption, and *rejected* if evidence contradicted the hypothesized pattern.

The interviews revealed several key points.

- Low levels of information. Parents lacked easily accessible information about the location of vaccination sites, the fact that the HPV vaccine is provided free of charge, and the age range to get vaccinated. They were also unaware that the HPV vaccine is offered through the non-pediatric vaccination scheme and lacked understanding of the consequences of HPV infections.
- Mistrust. Almost half of the parents interviewed recalled the Carmen de Bolívar incident, where girls experienced adverse effects from the HPV vaccine. This memory heavily influenced their perception of vaccine risks (availability heuristic) despite the overwhelming evidence supporting the vaccine's safety.
- Biased perception of risks. The lack of strong endorsement for the vaccine from the government and medical professionals appeared to validate parents' concerns regarding the vaccine's legitimacy and safety.
- Social norms. Parents indicated they were more likely to vaccinate their daughters if they perceived other parents doing the same. However, most parents were unaware of the vaccination decisions made by other parents, which created uncertainty about prevailing social norms.

The insights obtained from the analytical model and these interviews enabled us to identify the constraints affecting our target population and to develop specific behavioral tools to address each of them effectively.⁹

 $^{^{8}}$ Interviews were conducted by a team of two health professionals, one interviewer, and one note taker. They were not recorded.

⁹Evidence obtained from a similar experiment conducted in Bogotá served as a foundation for developing this intervention (Maldonado et al., 2024; Martinez Villarreal et al., 2023).

2.3 Treatments

According to the analytical model and diagnostic findings, HPV vaccination rates could be improved by addressing parents' perceptions and information gaps. The diagnostic revealed that individuals often deviate from fully rational decision-making, prompting a focus on behaviors influencing each parameter of the analytical model, particularly those related to the cost function. The analysis identified several behaviors impacting these parameters: lack of information was linked to physical costs, (F), and opportunity costs, (opp), mistrust and biased risk perceptions were associated with perceived side effects of vaccination, (S), and social norms were connected to psychological costs, (psych). This understanding enabled the application of behavioral economics to target key parameters in the decision-making model.

Based on these insights, a range of strategies was identified to influence decision-making effectively. These included providing clear and concise information, using framing approaches to emphasize the benefits of vaccination, sending reminders to overcome procrastination and forgetfulness, personalizing information, highlighting descriptive and prescriptive social norms, making key elements more visible and prominent, and using defaults to mitigate cognitive overload and present bias.

Building on these strategies, four distinct treatments were designed: i) information provision, ii) social norms messaging, iii) enhancing trust in the vaccine, and iv) message framing.

- Information Provision. The first treatment focuses on providing information to address complacency and the lack of knowledge about HPV infection and related diseases. Messages under this treatment aimed to raise awareness about critical aspects of the HPV vaccine, including its availability at no cost, the recommended age range (9-17) for vaccination, and the location of vaccination centers. Additionally, these messages emphasized the vaccine's effectiveness in reducing the risk of cervical cancer without mentioning its transmission through sexual activity.
- Social Norms. The second treatment incorporates social norms into the messages. This approach is strongly supported by evidence suggesting that focusing solely on knowledge and awareness is insufficient. It highlights the importance of external influences, such as the local context and community behaviors (Aggarwal et al., 2024). The messages included prescriptive, dynamic, and trending positive norms, as well as a combination of them.¹⁰ Research suggests that dynamic and trending norms can be

¹⁰Prescriptive norms refer to socially accepted rules or expectations about how individuals should behave, regardless of whether people actually follow them (e.g., 'Parents should vaccinate their children against HPV'). Dynamic norms highlight how behaviors and attitudes change over time, signaling that many people

particularly effective in encouraging behavior change because they create a sense of momentum and social validation (Martinez Villarreal et al., 2023; Milkman et al., 2022; Sparkman and Walton, 2017).

- Building Trust in Vaccines. The third treatment addresses the lack of confidence in HPV vaccines by relying on recommendations from trusted sources, such as doctors and the Secretariat of Health of Cali. These endorsements act as strong signals of the vaccine's safety and benefits, aiming to build trust among parents.
- Framing Strategies. The fourth treatment focuses on changing the framing of messages to influence decision-making:
 - Completion Bias: Messages emphasized the girl's incomplete vaccination schedule, leveraging the principle of completion bias to motivate parents to ensure their daughters complete the required vaccinations.
 - Establishing Reference Points: Messages framed the HPV vaccine as being as safe as other vaccines in the vaccination schedule, aiming to normalize its safety (Cox et al., 2010a).
 - Endowment Effect: Messages suggested that the vaccine already "belongs to the girl," leveraging the endowment effect, which increases the perceived value of something when it is viewed as already possessed (Milkman et al., 2022).
 - Loss Aversion: Messages emphasized the potential consequences of not vaccinating, such as the risk of cervical cancer, to leverage loss aversion and encourage vaccination (Gerend and Shepherd, 2007; Nan, 2012).

2.4 Intervention Design

The intervention was conducted in Cali, Colombia, from January 10 to February 28, 2023. In partnership with the Secretariat of Health of Cali, we obtained access to the client database of the health insurance company SURA¹¹. This company was chosen due to the high quality of

are adopting a particular behavior (e.g., 'More parents are choosing to vaccinate their children each year'). Trending norms emphasize the increasing popularity of a behavior by presenting it as part of a broader trend, often using historical data to illustrate the shift (e.g., 'Since 2016, the number of parents vaccinating their children has increased by 149%').

¹¹Rigorous measures were implemented to ensure secure data handling in compliance with personal data protection regulations. The project was approved by the Institutional Review Board (IRB) of Innovations for Poverty Action (IRB Protocol No. 4275), assuring adherence to the highest ethical and security standards. Access to the data was restricted to authorized personnel only, guaranteeing that only those with a legitimate need could access the information. Deidentified information was used for subsequent analysis.

their data, which facilitated the identification of those SURA members with daughters aged 9 to 17^{12} . After identifying the parents of girls within this age range, they were randomly assigned into six equal groups: control group, placebo, informational treatment, social norms treatment, trust treatment, and framing treatment. The randomization was stratified based on whether a daughter was 17 years old or younger and the household income level¹³.

Each group received weekly SMS messages¹⁴ to encourage vaccination using various behavioral strategies, which also served as reminders to parents¹⁵. Messages were sent to each group every Tuesday for eight weeks, except for the control group, which did not receive any messages. These messages were sent at different times throughout the day to increase the probability that parents would receive them at appropriate times. The placebo group received a message each week that was unrelated to HPV vaccines (e.g., ''Hello [daughter's name]'s mom, we have the health services that your family needs.").¹⁶

The content of the messages depended on the treatment assigned to each group¹⁷. These treatments were determined through an in-depth understanding of the sample needs obtained from interviews conducted during the diagnosis exercise. Behavioral barriers, such as biases and heuristics, were identified, and the tools to overcome them were determined. For instance, before this intervention, there was no tool available to locate the nearest health center to receive the vaccine. As part of this intervention, the Secretariat of Health developed a map of the city referencing all the health centers where the HPV vaccine was administered. A link to this map was distributed to all treatment groups during the sixth

¹²There is no record of any child for whom messages about vaccination were sent to both parents. Each child was linked to a single contact number for the insured parent.

¹³The income level is divided into three groups: i) those that belong to the level 1 or 2 of System of Identification of Social Program Beneficiaries (SISBEN), which identifies families in extreme and moderate poverty; ii) those whose income is less than 2 times the Minimum Legal Monthly Wages in Force (SMLMV, by its acronym in Spanish) of Colombia; iii) those whose income is higher than 2 times the SMLMV of Colombia.

¹⁴The use of SMS in this study was inspired by a similar intervention implemented in Bogotá in 2021, where text messages successfully encouraged vaccination through behavioral strategies. Given its effectiveness and prior adoption by the Bogotá Health Secretariat, SMS was selected as a trusted communication channel. Furthermore, SMS enables direct and cost-effective outreach, ensuring message delivery without requiring Internet access. For the current study, the most effective messages from the Bogotá intervention were adapted to the local context of Cali.

¹⁵The intervention targeted both parents, as the contact number provided by SURA was linked to the insured adult, who could be either the mother or the father. However, the messages were primarily directed toward mothers, as most of the contact numbers in the database were linked to them. As part of the design phase of a similar experiment in Bogotá, we also conducted an exercise in which 100 parent contact numbers were randomly selected to receive a call, and only one of the parents who picked up the phone was a father.

¹⁶The SMS were sent through ALTIRIA, a platform that allowed researchers to manage message sending directly, ensuring complete control over treatment delivery.

¹⁷See Table A5 and Table A6 for the messages sent.

week of the intervention.

During odd weeks (i.e., weeks 1, 3, etc.), the content was tailored to the treatment, while in the remaining weeks, the messages included information that would reduce barriers to action (see Figure 1). The information sent during even weeks (i.e., weeks 2, 4, etc.) was common for all treatment groups. All text messages sent to the parents were personalized using their daughter's name and signed by the Secretariat of Health of Cali to increase parents' confidence in the messages.

	Week 1	Week 2	Week 3	Week 4	Week 5	Week 6	Week 7	Week 8
Control	No msg	No msg	No msg	No msg	No msg	No msg	No msg	No msg
Placebo	Public health	Public health	Public health	Public health	Public health	Public health	Public health	Public health
T1: Information	Free	Age	Place	CCU	Call to action	Мар	Reminders (1=2)	Simple reminder
T2: Social Norms	Prescriptive norms	Free/age	Dynamic norm	Place / CCU	Trending norm	Call to action / Map	Prescriptive + Trending + Age	Simple reminder
T3: Trust	Dr.'s recommend	Free/age	Sec Salud recommend	Place / CCU	Signaling	Call to action / Map	Dr. + Sec Salud + Age	Simple reminder
T4: Framing	Pseudo sets	Free/age	Reference points	Place / CCU	Soft-default + endowment	Call to action / Map	Loss framing + age	Simple reminder

Figure 1: Content of Messages by Treatment

Note: CCU refers to information related to Cervical Cancer

2.5 Data

The Secretariat of Health provided administrative data on eligible girls from the insurance company SURA. Based on this sample, the experimental groups were created. The initial sample consisted of 15,231 parents, with 97.04% of their daughters having not received any previous dose. However, after analyzing the data, it was found that some girls had already completed the HPV vaccination scheme (two doses) prior to the intervention, reducing the sample size to 15,178.

Descriptive statistics are provided in Table 1. Girls under a subsidized scheme represent 13.2% of the sample. Those under this scheme have access to health services through a national subsidy because their categorization in the System of Identification of Social Assistance Beneficiaries (SISBEN) identifies them as being in extreme poverty, poverty, and

vulnerability. According to the National Administrative Department of Statistics (DANE), 15.7% of Cali's population had a per capita household income below the poverty line in 2018 (DANE, 2018). Additionally, the average age of the girls is 13, and 11.20% of them are 17 years old, which is the age limit for receiving the HPV vaccine. Regarding socio-economic characteristics, the majority of participants in our sample (62.6%) come from middle-income households; in comparison, 35.2% of the population in Cali is considered middle-class (DANE, 2022). Finally, 3% of the girls reported having received at least one dose of the vaccine before the intervention.

The randomized sample is well-balanced in terms of observables, as shown in Table A1.¹⁸ The outcome variable, vaccine take-up, was provided by the health insurance.

	Total	Means (s.d.)						
	sample	Control (C)	Placebo (P)	Information (T_1)	Social norms (T_2)	$\begin{array}{c} \text{Trust} \\ (\text{T}_3) \end{array}$	$\begin{array}{c} \text{Framing} \\ (\text{T}_4) \end{array}$	
Subsidized	0.132	0.132 (0.338)	0.132 (0.339)	0.132 (0.338)	0.132 (0.338)	0.132 (0.338)	0.132 (0.338)	
Age	12.996	(0.000) 12.946 (2.610)	(0.000) 13.012 (2.642)	(0.000) 12.972 (2.627)	(0.000) 13.019 (2.647)	(0.000) 13.037 (2.616)	(2.636) 12.993 (2.624)	
17 years old	0.112	(2.019) 0.112 (0.315)	(2.042) 0.112 (0.315)	(2.027) 0.112 (0.315)	(2.047) 0.112 (0.215)	(2.010) 0.112 (0.315)	(2.034) 0.112 (0.315)	
Income		(0.313)	(0.313)	(0.315)	(0.313)	(0.313)	(0.313)	
Low income	0.132	0.132 (0.338)	0.132 (0.339)	0.132 (0.338)	0.132 (0.338)	0.132 (0.338)	0.132 (0.338)	
Medium income	0.626	(0.636) (0.627) (0.484)	0.626	0.627	0.626	0.626	0.626	
High income	0.242	(0.434) (0.242) (0.428)	(0.434) 0.242 (0.428)	(0.484) (0.242) (0.428)	$\begin{array}{c} (0.434) \\ 0.242 \\ (0.429) \end{array}$	(0.434) (0.242) (0.428)	$\begin{array}{c} (0.484) \\ 0.242 \\ (0.428) \end{array}$	
Previous doses								
At least one dose	0.030	0.033	0.032	0.028	0.023	0.034	0.028	
Complete scheme	0.003	(0.180) 0.003 (0.056)	(0.175) 0.002 (0.044)	(0.166) 0.004 (0.063)	(0.149) 0.004 (0.066)	(0.181) 0.005 (0.069)	(0.164) 0.003 (0.052)	
Total observations	$15,\!231$	2,539	2,538	2,539	2,538	2,538	2,539	

Table 1: Descriptive Statistics

Notes: Means and standard deviations (SD) are presented. SD are in parenthesis. Previous doses indicates if the girl has received any dose before the intervention began.

After carrying out the intervention, we collected the endline data in June 2023 to assess the impact four months after the implementation.

¹⁸Table A1 presents the pairwise comparisons of observable characteristics across groups, including control, placebo, and the four treatments (T_1, T_2, T_3, T_4) .

2.6 Empirical Strategy

We estimate the treatment effects using the following specification:

$$y_i = \alpha + \beta_j T_{ij} + X_i \Gamma + \theta_s + v_s$$

where y_i is the outcome variable, vaccination status. It takes the value 1 if the parent vaccinates their daughter and zero otherwise. T_{ij} represents the treatment j for the parent i, X_i is the set of covariates which includes whether a girl is under a subsidized scheme, age, and socioeconomic status, healthcare center visited, and if she has received a dose before the intervention, θ_s is the stratification variable (level of income and age), and v_s is the error term. OLS regressions are employed for data analysis.

3 Results

The study aimed to assess the effectiveness of SMS interventions to parents in increasing HPV vaccination rates¹⁹. It involved four different treatment groups: the informational SMS group, the social norms SMS group, the trust SMS group, and the framing SMS group. Table 2 presents the effect of each group four months after the intervention²⁰, and shows that all four treatments had a significant impact on vaccination rates. Compared to the control group, the informational SMS group saw a 2.8 percentage point (p.p.) increase, equivalent to a 48.3% rise. The social norms SMS group experienced a 2 p.p. increase, equivalent to a 34.5% rise. The trust SMS group demonstrated a 3.2 p.p. increase, equivalent to a 55.2% rise. Lastly, the framing SMS group displayed a 2.7 p.p. increase, equivalent to a 46.6% rise in the vaccination rate (see Figure 2). These findings demonstrate that SMS interventions based on behavioral insights can significantly benefit health prevention. Moreover, enhancing the decision-making process by increasing confidence in the vaccination uptake.

Additionally, we explored heterogeneous effects based on the dosage administered to the daughters. Table A2 estimates the effects on girls who had previously received a vaccine before the intervention versus those who had not. Findings suggest that girls who had received their first dose and were assigned to the Information and Framing SMS groups were more likely to receive their second dose (see Figure 3), resulting in increases of 13 percentage points (p.p.) and 12.5 p.p., respectively, in vaccination rates.

¹⁹Data analysis was conducted using Stata 17.

 $^{^{20}}$ The endline data were collected in June 2023.

Figure 2: Effect on HPV Vaccination Uptake by Treatment



control group. The control group effect is 5.8 p.p., represented by the horizontal line. It includes 99.9%, 99% and 95% confidence intervals.

Furthermore, we analyzed heterogeneous effects by the age of the daughters, differentiating between those under 17 and those who were 17 (refer to Table A3). This comparison is based on the fact that once daughters turn 18 years old, the vaccine is no longer free. By including this heterogeneity, we aim to address how the urgency faced by parents with 17-year-old daughters, who are approaching the deadline to receive the vaccine for free, may affect the treatment effects.

Figure A1 shows that those under 17 who received the Information and the Trust SMS were more likely to get vaccinated. Conversely, there does not seem to be a significant effect supporting the hypothesis that a sense of urgency among parents of 17-year-old daughters influences vaccination rates.

We also analyzed the impact based on household income level (see Table A4). Figure A2 presents the findings, indicating that the effects of treatments did not significantly differ among middle and high-income households. However, both these income groups were more likely to get vaccinated compared to the lower-income group, particularly those assigned to the Framing and Information groups.

			Model 1	Model 2
Treatment				
Placebo			0.002	0.003
			(0.007)	(0.007)
Information			0.026^{***}	0.028***
			(0.007)	(0.007)
Social norms			0.019^{**}	0.020**
			(0.007)	(0.007)
Trust			0.030***	0.032***
			(0.007)	(0.007)
Framing			0.026***	0.027***
			(0.007)	(0.007)
Constant			0.058 ***	-0.045
			(0.005)	(0.030)
Observations			15,178	15,178
R-squared			0.002	0.031
T-test				
Placebo	=	Information	0.0015	0.0006
Placebo	=	Social norms	0.0204	0.0196
Placebo	=	Trust	0.0002	0.0001
Placebo	=	Framing	0.0013	0.0008
Information	=	Social norms	0.3973	0.2805
Information	=	Trust	0.5474	0.5829
Information	=	Framing	0.9681	0.9410
Social norms	=	Trust	0.1477	0.1037
Social norms	=	Framing	0.3752	0.3145
Trust	=	Framing	0.5742	0.5331
Strata fixed effects			No	Yes
Covariates			No	Yes

Table 2: Effect on HPV Vaccine Uptake

Models 1 and 2 capture the effect of each of the treatments on vaccine take-up following the main model under two especifications. Model 2 includes as covariates whether a girl is under subsidized scheme, whether she has received a dose before, healthcare center visited, and the stratification variable which includes level of income and age. *** p<0.001, ** p<0.001, * p<0.05

3.1 Cost-effectiveness

The intervention significantly increased vaccination rates, but was it cost-effective? It utilized an existing vaccination infrastructure. Vaccines were already procured and provided at no



Figure 3: Effect on HPV Vaccination by Dose Received

cost, and SURA possessed the necessary technological infrastructure for message delivery. Therefore, the primary costs of the intervention were related to the personnel responsible for message delivery and the cost of sending the messages.

The intervention reached 15,231 parents via SMS and delivered 121,848 messages during the eight-week intervention period. Each message cost 8 COP, resulting in a total message cost of 974,784 COP (USD 200). In terms of personnel, a part-time tech professional worked one day per week on designing, testing, and delivering the messages, accumulating a total of 64 hours at a rate of 40,000 COP per hour. This resulted in a personnel cost of 2,560,000 COP (USD 512).²¹ Consequently, the total cost of the intervention was USD 712.

Considering that the intervention reached 15,231 girls, the messaging cost per girl was USD 0.05 (USD 712 divided by 15,231). The cost-effectiveness ratio, calculated as the cost per additional vaccinated girl, was USD 1.56 for messages enhancing trust in the vaccine (USD 0.05 divided by 0.032), USD 1.79 for the informational group (USD 0.05 divided by

 $^{^{21}}$ Cost information obtained from: Maldonado et al. (2024). The amounts are reported in 2023 USD, reflecting the exchange rate on the first day of the intervention (January 10, 2023).

0.028), USD 1.85 for the framing treatment (USD 0.05 divided by 0.027), and USD 2.50 for the social norms group (USD 0.05 divided by 0.02). In other words, the cost of achieving one additional vaccinated girl ranged between USD 1.5 and USD 2.5, depending on the type of messaging strategy.

These cost-effectiveness ratios, ranging from USD 1.5 to USD 2.5, are consistent with and lower than those reported in similar interventions. For instance, other studies have reported higher ratios, ranging from USD 5.5 to USD 7.9 (Athey et al., 2023; Busso et al., 2015; Kawakatsu et al., 2020; Maldonado et al., 2024).

The economic benefits of this intervention far outweigh its costs. For example, Cali has an incidence rate of 20.1 and a mortality rate of 7 per 100,000 for cervical cancer (Muñoz and Bravo, 2012). With a vaccine effectiveness rate of 90%, vaccinating 100 girls would prevent approximately 0.018 cases of cervical cancer and 0.0063 deaths. Assuming an average annual income of USD 9,500 and an extended lifespan of 15 years (the average age of cervical cancer detection is 50), the economic benefit per vaccinated girl—considering only the prevention of deaths—is approximately USD 8.98. This benefit would increase substantially if the income losses of survivors and medical costs associated with treating cervical cancer were considered.

Thus, based on these cost-effectiveness ratios, the intervention generates between USD 3.6 and USD 5.75 in economic benefits for every dollar spent. This indicates a highly cost-effective intervention with substantial public health and economic returns.

4 Discussion

The comprehensive findings of this study shed light on crucial aspects surrounding HPV vaccination uptake and the effectiveness of behaviorally informed SMS interventions in promoting vaccination among parents in a high vaccine hesitancy scenario. Significant improvements in vaccination rates were observed across all treatment groups—informational, social norms, trust, and framing. These findings emphasize the power of behavioral insights in designing tailored interventions that address specific barriers to vaccination. Moreover, the differential effects observed among treatment groups, particularly regarding prior vaccination status, highlight the nuanced behavioral dynamics that influence vaccination decision-making.

The study underscores that the content of the message is fundamental. Across the different treatments, including the placebo (messages without behavioral insights), it became evident that simply sending a message is insufficient. An exhaustive diagnosis of the target population is crucial to designing interventions that effectively address specific barriers. The importance of such interventions is particularly evident in the context of Colombia's national HPV vaccination program, which represents a major public health investment of approximately USD 100 million aimed at protecting girls aged 9 to 17^{22} . By reducing psychological and informational barriers, behavioral strategies amplify the impact of these initiatives, which aim to curb cervical cancer incidence and death rates (ICO/IARC, 2023; Liga Colombiana contra el Cáncer, 2022).

Our study demonstrates that it is possible to restore vaccination rates even in the face of a crisis eroding confidence in vaccines by employing behavioral interventions. Specifically, the results suggest that if declining vaccination rates stem from distrust, a targeted message reinforcing confidence in the vaccine, supported by comprehensive information and endorsed by a healthcare professional, can effectively reverse some of the downward trends in vaccination rates.

This is especially relevant in low- and middle-income countries like Colombia, where negative perceptions about HPV vaccination persist following a highly publicized adverse event. In this context, the trust-based intervention led to a 55% increase in vaccination uptake compared to the control group, showing that well-targeted behavioral messages can effectively restore at least some public trust and boost vaccination rates.

This study also aims to bridge the existing literature gap by identifying strategies to address the decline in vaccine uptake in areas where adverse events have diminished vaccine confidence. This is particularly pertinent given the current climate of declining vaccine confidence (Larson et al., 2011). Some experiences from around the world have shown that mishandling a vaccine-related issue can lead to its rapid escalation and continued persistence (Aggarwal et al., 2024; Gauna et al., 2023; Huon et al., 2020; Tsu et al., 2021; Sekine et al., 2021; Simms et al., 2020; Mendes Lobão et al., 2018). For instance, in Japan, the suspension of proactive government recommendations following an adverse event led to a significant drop in HPV vaccination rates (Simms et al., 2020). Similarly, in Denmark, sensationalized media reports of adverse events resulted in negative publicity and a considerable decrease in vaccine uptake (Suppli et al., 2018). Our findings highlight the importance of well-managed strategies to mitigate the long-term effects of such events and help restore vaccination rates.

In conclusion, this study underscores the potential of using innovative behaviorallyinformed communication strategies to address vaccine hesitancy in challenging environments. Public health practitioners can improve vaccination uptake, even after an adverse event,

²²According to the Ministry of Health of Colombia, the HPV vaccination program is offered to girls aged 9 to 17 years and to students in grades 4 through 11, as long as they are at least 9 years old (Ministerio de Salud de Colombia, 2023).

by implementing tailored SMS interventions that specifically address the barriers and psychological factors influencing parental decision-making. Moreover, these strategies offer a cost-effective solution that can be adapted to various public health crises beyond HPV vaccination. Future research should explore how these insights can be applied across different health contexts, ensuring that behavioral science continues to inform the design of effective, scalable public health interventions that reduce the global burden of vaccine-preventable diseases.

References

- ACS (2024). Global Cancer Facts Figures 5th Edition. Available online at: https://www. cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/ global-cancer-facts-and-figures/global-cancer-facts-and-figures-2024.pdf [Accessed on Sep 09, 2024].
- Aggarwal, S., Agarwal, P., and Gupta, N. (2024). A comprehensive narrative review of challenges and facilitators in the implementation of various HPV vaccination program worldwide. *Cancer Medicine*, 13(3):e6862.
- Agosti, J. M. and Goldie, S. J. (2007). Introducing HPV vaccine in developing countries—key challenges and issues. *New England Journal of Medicine*, 356(19):1908–1910.
- Amadane, M., de Pree, C., Viviano, M., Vassilakos, P., Jeannot, E., and Petignat, P. (2019). Characteristics of HPV-unvaccinated undergraduate health students in Switzerland, a cross sectional study. Archives of Public Health, 77:1–6.
- Andrus, J. K., Lewis, M. J., Goldie, S. J., García, P. J., Winkler, J. L., Ruiz-Matus, C., and de Quadros, C. A. (2008). Human papillomavirus vaccine policy and delivery in Latin America and the Caribbean. *Vaccine*, 26:L80–L87.
- Athey, S., Grabarz, K., Luca, M., and Wernerfelt, N. (2023). Digital public health interventions at scale: The impact of social media advertising on beliefs and outcomes related to covid vaccines. *Proceedings of the National Academy of Sciences*, 120(5):e2208110120.
- Austin, B. and Morgan, H. (2019). Improving human papillomavirus vaccine uptake in the family practice setting. *The Journal for Nurse Practitioners*, 15(6):e123–e125.
- Baseman, J. G. and Koutsky, L. A. (2005). The epidemiology of human papillomavirus infections. *Journal of clinical virology*, 32:16–24.
- Berenson, A. B., Rahman, M., Hirth, J. M., Rupp, R. E., and Sarpong, K. O. (2016). A human papillomavirus vaccination program for low-income postpartum women. American journal of obstetrics and gynecology, 215(3):318–e1.
- Betsch, C., Böhm, R., and Chapman, G. B. (2015). Using behavioral insights to increase vaccination policy effectiveness. *Policy Insights from the Behavioral and Brain Sciences*, 2(1):61–73.
- Betta, S., Castellini, G., Acampora, M., and Barello, S. (2022). The effect of message framing on COVID-19 vaccination intentions among the younger age population groups: results from an experimental study in the Italian context. *Vaccines*, 10(4):559.
- Brabin, L., Roberts, S. A., Stretch, R., Baxter, D., Chambers, G., Kitchener, H., and Mc-Cann, R. (2008). Uptake of first two doses of human papillomavirus vaccine by adolescent schoolgirls in Manchester: prospective cohort study. *Bmj*, 336(7652):1056–1058.

- Brianti, P., De Flammineis, E., Mercuri, S. R., et al. (2017). Review of HPV-related diseases and cancers. *New Microbiol*, 40(2):80–85.
- Bruni, L., Saura-Lázaro, A., Montoliu, A., Brotons, M., Alemany, L., Diallo, M. S., Afsar, O. Z., LaMontagne, D. S., Mosina, L., Contreras, M., et al. (2021a). HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010–2019. *Preventive medicine*, 144:106399.
- Bruni, L., Saura-Lázaro, A., Montoliu, A., Brotons, M., Alemany, L., Diallo, M. S., Afsar, O. Z., LaMontagne, D. S., Mosina, L., Contreras, M., et al. (2021b). Hpv vaccination introduction worldwide and who and unicef estimates of national hpv immunization coverage 2010–2019. *Preventive medicine*, 144:106399.
- Busso, M., Cristia, J., and Humpage, S. (2015). Did you get your shots? experimental evidence on the role of reminders. *Journal of Health Economics*, 44:226–237.
- Carrasquilla, G., Velandia, D., Caceres, D., and Gomez, J. (2017). Cost-effectiveness evaluation of a two-dose human papillomavirus vaccination schedule in colombia. *Value in Health*, 20(9):A931.
- Cartmell, K. B., Mzik, C. R., Sundstrom, B. L., Luque, J. S., White, A., and Young-Pierce, J. (2019). HPV vaccination communication messages, messengers, and messaging strategies. *Journal of Cancer Education*, 34:1014–1023.
- Cartmell, K. B., Young-Pierce, J., McGue, S., Alberg, A. J., Luque, J. S., Zubizarreta, M., and Brandt, H. M. (2018). Barriers, facilitators, and potential strategies for increasing HPV vaccination: A statewide assessment to inform action. *Papillomavirus Research*, 5:21–31.
- Castro, C., Marin, M., Torres Agredo, M., and Muñoz, N. (2020). Vacunación contra el VPH en colombia. Available online at: https://www.hpvworld.com/media/29/media_ section/9/8/2798/hpvworld-142.pdf [Accessed on Jul 12, 2024].
- Castro, C. J. (2018). The Unbelievable Story of the HPV Vaccination Program in Colombia... From a Beautiful Dream to a Nightmare! *Journal of Global Oncology*, 4:169–169.
- Cates, J. R., Crandell, J. L., Diehl, S. J., and Coyne-Beasley, T. (2018). Immunization effects of a communication intervention to promote preteen HPV vaccination in primary care practices. *Vaccine*, 36(1):122–127.
- CDC (2019). HPV Vaccine Schedule and Dosing. Available online at: https://www.cdc. gov/hpv/hcp/schedules-recommendations.html [Accessed on Jul 16, 2024].
- CDC (2024). About genital HPV infection. Available online at: https://www.cdc.gov/ sti/about/about-genital-hpv-infection.html [Accessed on Jul 12, 2024].

- Cordoba-Sanchez, V., Lemos, M., Tamayo-Lopera, D. A., and Sheinfeld Gorin, S. (2022). HPV-vaccine hesitancy in Colombia: a mixed-methods study. *Vaccines*, 10(8):1187.
- Cox, D. S., Cox, A. D., Sturm, L., and Zimet, G. (2010a). Behavioral interventions to increase hpv vaccination acceptability among mothers of young girls. *Health Psychology*, 29(1):29.
- Cox, D. S., Cox, A. D., Sturm, L., and Zimet, G. (2010b). Behavioral interventions to increase HPV vaccination acceptability among mothers of young girls. *Health Psychology*, 29(1):29.
- Dai, H., Saccardo, S., Han, M., Roh, L., Raja, N., Vangala, S., Modi, H., Pandya, S., Sloyan, M., and Croymans, D. (2021). Behavioural nudges increase covid-19 vaccinations. *Nature*, 597:404–409.
- DANE (2018). Boletín Técnico. Pobreza monetaria en Colombia. Available online at: https://www.dane.gov.co/files/investigaciones/condiciones_vida/pobreza/ 2018/bt_pobreza_monetaria_18.pdf [Accessed on Jul 15, 2024].
- DANE (2022). Cali en cifras: Demografía, economía y mercado laboral. Available online at: https://www.dane.gov.co/files/investigaciones/ planes-departamentos-ciudades/220322-Foro-Cali-en-cifras.pdf [Accessed on Jul 15, 2024].
- De la Hoz-Restrepo, F., Castañeda-Orjuela, C., Carrasquilla, M., and Alvis, N. (2012). Pcn65 cost-effectiveness analysis of introducing hpv vaccines in colombian women. Value in Health, 15(7):A420.
- de Martel, C., Georges, D., Bray, F., Ferlay, J., and Clifford, G. M. (2020). Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. *The Lancet* global health, 8(2):e180–e190.
- Denny, L. (2005). The prevention of cervical cancer in developing countries. BJOG: An International Journal of Obstetrics & Gynaecology, 112(9):1204–1212.
- Donahue, K., Hendrix, K., Sturm, L., and Zimet, G. (2018). Provider communication and mothers' willingness to vaccinate against human papillomavirus and influenza: a randomized health messaging trial. *Academic pediatrics*, 18(2):145–153.
- Duckworth, A. L. and Milkman, K. L. (2022). A guide to megastudies. *PNAS nexus*, 1(5):pgac214.
- Ebrahimi, N., Yousefi, Z., Khosravi, G., Malayeri, F. E., Golabi, M., Askarzadeh, M., Shams, M. H., Ghezelbash, B., and Eskandari, N. (2023). Human papillomavirus vaccination in low-and middle-income countries: progression, barriers, and future prospective. *Frontiers* in Immunology, 14:1150238.

- Escoffery, C., Petagna, C., Agnone, C., Perez, S., Saber, L. B., Ryan, G., Dhir, M., Sekar, S., Yeager, K. A., Biddell, C. B., et al. (2023). A systematic review of interventions to promote HPV vaccination globally. *BMC Public Health*, 23(1):1262.
- Ferrer, H. B., Audrey, S., Trotter, C., and Hickman, M. (2015). An appraisal of theoretical approaches to examining behaviours in relation to human papillomavirus (HPV) vaccination of young women. *Preventive medicine*, 81:122–131.
- Franco, E. L., Tsu, V., Herrero, R., Lazcano-Ponce, E., Hildesheim, A., Muñoz, N., Murillo, R., Sánchez, G. I., and Andrus, J. K. (2008). Integration of human papillomavirus vVaccination and cervical cancer screening in Latin America and the Caribbean. *Vaccine*, 26:L88–L95.
- Gainforth, H. L., Cao, W., and Latimer-Cheung, A. E. (2012). Message framing and parents' intentions to have their children vaccinated against HPV. *Public Health Nursing*, 29(6):542–552.
- Gauna, F., Verger, P., Fressard, L., Jardin, M., Ward, J. K., and Peretti-Watel, P. (2023). Vaccine hesitancy about the HPV vaccine among French young women and their parents: a telephone survey. *BMC Public Health*, 23(1):628.
- Gerend, M. A. and Shepherd, J. E. (2007). Using message framing to promote acceptance of the human papillomavirus vaccine. *Health Psychology*, 26(6):745.
- Guzman-Holst, A., DeAntonio, R., Prado-Cohrs, D., and Juliao, P. (2020). Barriers to vaccination in Latin America: A systematic literature review. *Vaccine*, 38(3):470–481.
- Handler, M. Z., Handler, N. S., Majewski, S., and Schwartz, R. A. (2015). Human papillomavirus vaccine trials and tribulations: clinical perspectives. *Journal of the American Academy of Dermatology*, 73(5):743–756.
- Huang, S. (2024). The Current Status of the HPV Vaccine Worldwide. *MedScien*, 1(7).
- Huon, J.-F., Gregoire, A., Meireles, A., Lefebvre, M., Péré, M., Coutherut, J., Biron, C., Raffi, F., and Briend-Godet, V. (2020). Evaluation of the acceptability in France of the vaccine against papillomavirus (HPV) among middle and high school students and their parents. *PLoS One*, 15(10):e0234693.
- IARC and WHO (2022). Cancer Today. Available online at: https://gco.iarc.fr/today/ en [Accessed on Jul 12, 2024].
- ICO/IARC (2023). Colombia: Human Papillomavirus and Related Cancers, Fact Sheet. Available online at: https://hpvcentre.net/statistics/reports/COL_FS.pdf? t=1661332364051#:~:text=I.,die%20from%20the%20dis%2D%20ease [Accessed on Sep 13, 2024].

- Jacobs-Wingo, J. L., Jim, C. C., and Groom, A. V. (2017). Human papillomavirus vaccine uptake: increase for American Indian adolescents, 2013–2015. American journal of preventive medicine, 53(2):162–168.
- Kaarthigeyan, K. (2012). Cervical cancer in India and HPV vaccination. Indian Journal of Medical and Paediatric Oncology, 33(01):7–12.
- Kahn, J. A., Rosenthal, S. L., Hamann, T., and Bernstein, D. I. (2003). Attitudes about human papillomavirus vaccine in young women. *International journal of STD & AIDS*, 14(5):300–306.
- Karing, A. (2018). Social signaling and childhood immunization: A field experiment in Sierra Leone. University of California, Berkeley, 2.
- Kaul, S., Do, T. Q. N., Hsu, E., Schmeler, K. M., Montealegre, J. R., and Rodriguez, A. M. (2019). School-based human papillomavirus vaccination program for increasing vaccine uptake in an underserved area in Texas. *Papillomavirus Research*, 8:100189.
- Kawakatsu, Y., Oyeniyi Adesina, A., Kadoi, N., and Aiga, H. (2020). Cost-effectiveness of sms appointment reminders in increasing vaccination uptake in lagos, nigeria: A multicentered randomized controlled trial. *Vaccine*, 38(42):6600–6608.
- Kempe, A., O'Leary, S. T., Markowitz, L. E., Crane, L. A., Hurley, L. P., Brtnikova, M., Beaty, B. L., Meites, E., Stokley, S., and Lindley, M. C. (2019). HPV vaccine delivery practices by primary care physicians. *Pediatrics*, 144(4).
- Kharbanda, E. O., Stockwell, M. S., Fox, H. W., Andres, R., Lara, M., and Rickert, V. I. (2011). Text message reminders to promote human papillomavirus vaccination. *Vaccine*, 29(14):2537–2541.
- Larson, H. J., Cooper, L. Z., Eskola, J., Katz, S. L., and Ratzan, S. (2011). Addressing the vaccine confidence gap. *The Lancet*, 378(9790):526–535.
- Lehmann, C. E., Brady, R. C., Battley, R. O., and Huggins, J. L. (2016). Adolescent vaccination strategies: interventions to increase coverage. *Pediatric Drugs*, 18:273–285.
- Lei, J., Ploner, A., Elfström, K. M., Wang, J., Roth, A., Fang, F., Sundström, K., Dillner, J., and Sparén, P. (2020). Hpv vaccination and the risk of invasive cervical cancer. New England Journal of Medicine, 383(14):1340–1348.
- Liga Colombiana contra el Cáncer (2022). Cáncer de cuello uterino. Available online at: https://www.ligacancercolombia.org/wp-content/uploads/2021/10/Ca% CC%81ncer-de-Cuello-Uterino-mar_2022.pdf [Accessed on Sep 13, 2024].
- Luciani, S. and Andrus, J. K. (2008). A Pan American Health Organization strategy for cervical cancer prevention and control in Latin America and the Caribbean. *Reproductive health matters*, 16(32):59–66.

- Luciani, S., Bruni, L., Agurto, I., and Ruiz-Matus, C. (2018). HPV vaccine implementation and monitoring in Latin America. *Salud publica de Mexico*, 60(6):683–692.
- Luvisaro, B. M. O., Silva, T. P. R. d., Silva, T. M. R. d., Lachtim, S. A. F., Souza, J. F. A., and Matozinhos, F. P. (2022). Environmental factors associated with human papillomavirus vaccine coverage in adolescents: 2016-2020 analysis. *Revista latino-americana de enfermagem*, 30(spe):e3804.
- Machado, C. V., Lima, L. D. d., and Viana, L. d. S. (2008a). Organization of traditional primary health care and the family health program in large cities in Rio de Janeiro state, Brazil. *Cadernos de Saúde Pública*, 24:s42–s57.
- Machado, C. V., Lima, L. D. d., and Viana, L. d. S. (2008b). Organization of traditional primary health care and the family health program in large cities in Rio de Janeiro state, Brazil. *Cadernos de Saúde Pública*, 24:s42–s57.
- Malagón, T., Franco, E. L., Tejada, R., and Vaccarella, S. (2024). Epidemiology of HPVassociated cancers past, present and future: towards prevention and elimination. *Nature Reviews Clinical Oncology*, pages 1–17.
- Maldonado, S., Martinez Villarreal, D., and Diaz, L. (2024). Building a shield together: Addressing low vaccine uptake against cancer through social norms. Technical report.
- Marchetti, R. L., Gallucci-Neto, J., Kurcgant, D., Proença, I. C. G. F., Valiengo, L. d. C. L., Fiore, L. A., Pinto, L. F., Maranhão, A. G. K., da Costa Oliveira, M. T., and de Oliveira, L. H. (2020). Immunization stress-related responses presenting as psychogenic non-epileptic seizures following HPV vaccination in Rio Branco, Brazil. Vaccine, 38(43):6714–6720.
- Marshall, H. S., Collins, J., Sullivan, T., Tooher, R., O'Keefe, M., Skinner, S. R., Watson, M., Burgess, T., Ashmeade, H., and Braunack-Mayer, A. (2013). Parental and societal support for adolescent immunization through school based immunization programs. *Vaccine*, 31(30):3059–3064.
- Martinez Villarreal, D. and Díaz, L. M. (2022). The case HPV vaccination in Colombia A behavioral economics toolkit.
- Martinez Villarreal, D., Díaz, L. M., and Maldonado, S. (2023). Nudging the trendsetters: Increasing second-dose HPV vaccination in Bogota, Colombia.
- Mays, R. M., Sturm, L. A., and Zimet, G. D. (2004). Parental perspectives on vaccinating children against sexually transmitted infections. *Social science & medicine*, 58(7):1405–1413.
- Mendes Lobão, W., Duarte, F. G., Burns, J. D., de Souza Teles Santos, C. A., Chagas de Almeida, M. C., Reingold, A., and Duarte Moreira, E. (2018). Low coverage of hpv

vaccination in the national immunization programme in brazil: Parental vaccine refusal or barriers in health-service based vaccine delivery? *PloS one*, 13(11):e0206726.

- Milkman, K. L., Gandhi, L., Patel, M. S., Graci, H. N., Gromet, D. M., Ho, H., Kay, J. S., Lee, T. W., Rothschild, J., Bogard, J. E., et al. (2022). A 680,000-person megastudy of nudges to encourage vaccination in pharmacies. *Proceedings of the National Academy of Sciences*, 119(6):e2115126119.
- Milkman, K. L., Gromet, D., and Ho, H. e. a. (2021a). Megastudies improve the impact of applied behavioural science. *Nature*, 600:478–483.
- Milkman, K. L., Patel, M. S., Gandhi, L., and Duckworth, A. L. e. a. (2021b). A megastudy of text-based nudges encouraging patients to get vaccinated at an upcoming doctor's appointment. *PNAS*, 118(20).
- Ministerio de Salud de Colombia (2023). Verdades y mentiras sobre la vacuna contra el cáncer de cuello uterino. Available online at: https://www.minsalud.gov.co/Paginas/ Verdades-mentiras-sobre-la-vacuna-contra-cancer-cuello-uterino.aspx [Accessed on Sep 13, 2024].
- Mortensen, C. R., Neel, R., Cialdini, R. B., Jaeger, C. M., Jacobson, R. P., and Ringel, M. M. (2019). Trending norms: A lever for encouraging behaviors performed by the minority. *Social Psychological and Personality Science*, 10(2):201–210.
- Muñoz, N. and Bravo, L. E. (2012). Epidemiology of cervical cancer in Colombia. Colombia Médica, 43(4):298–304.
- Muñoz, N., Franco, E. L., Herrero, R., Andrus, J. K., de Quadros, C., Goldie, S. J., and Bosch, F. X. (2008). Recommendations for cervical cancer prevention in Latin America and the Caribbean. *Vaccine*, 26:L96–L107.
- Murata, I. M. H., Gabrielloni, M. C., and Schirmer, J. (2012). Cobertura do Papanicolaou em mulheres de 25 a 59 anos de Maringá-PR, brasil. *Revista Brasileira de Cancerologia*, 58(3):409–415.
- Murillo, R., Almonte, M., Pereira, A., Ferrer, E., Gamboa, O. A., Jerónimo, J., and Lazcano-Ponce, E. (2008). Cervical cancer screening programs in Latin America and the Caribbean. *Vaccine*, 26:L37–L48.
- Nan, X. (2012). Relative persuasiveness of gain-versus loss-framed human papillomavirus vaccination messages for the present-and future-minded. *Human Communication Re*search, 38(1):72–94.
- Nogueira-Rodrigues, A., Bukowski, A., Paulino, E., St. Louis, J., Barrichello, A., Sternberg, C., Gifoni, M. A., Luciani, S., and Goss, P. E. (2017). An alert to Latin America: Current human papillomavirus vaccination trends highlight key barriers to successful implementation. *Cancer*, 123(12):2193–2199.

- Nogueira-Rodrigues, A., Flores, M., Macedo Neto, A., Braga, L., Vieira, C., de Sousa-Lima, R., de Andrade, D., Machado, K., and Guimarães, A. (2022a). HPV vaccination in latin america: Coverage status, implementation challenges and strategies to overcome it. *Front* Oncol, 26(12).
- Nogueira-Rodrigues, A., Flores, M. G., Macedo Neto, A. O., Braga, L. A. C., Vieira, C. M., Sousa-Lima, R. M. d., de Andrade, D. A. P., Machado, K. K., and Guimarães, A. P. G. (2022b). HPV vaccination in Latin America: Coverage status, implementation challenges and strategies to overcome it. *Frontiers in Oncology*, 12:984449.
- Nwanodi, O. (2017). Attitudes towards human papilloma virus vaccination in the latin american andean region. *Healthcare*, 5(3):55.
- Ogilvie, G. S., Remple, V. P., Marra, F., McNeil, S. A., Naus, M., Pielak, K. L., Ehlen, T. G., Dobson, S. R., Money, D. M., and Patrick, D. M. (2007). Parental intention to have daughters receive the human papillomavirus vaccine. *Cmaj*, 177(12):1506–1512.
- Olagoke, A., Hebert-Beirne, J., Floyd, B., Caskey, R., Boyd, A., and Molina, Y. (2023). The effectiveness of a religiously framed HPV vaccination message among Christian parents of unvaccinated adolescents in the United States. *Journal of Communication in Healthcare*, 16(2):215–224.
- O'Leary, S. T., Lockhart, S., Barnard, J., Furniss, A., Dickinson, M., Dempsey, A. F., Stokley, S., Federico, S., Bronsert, M., and Kempe, A. (2018). Exploring facilitators and barriers to initiation and completion of the human papillomavirus (HPV) vaccine series among parents of girls in a safety net system. *International journal of environmental* research and public health, 15(2):185.
- PAHO and WHO (2022). Cervical Cancer. Available online at: https://www.paho.org/ en/topics/cervical-cancer [Accessed on Jul 12, 2024].
- Paul, P. and Fabio, A. (2014). Literature review of HPV vaccine delivery strategies: considerations for school-and non-school based immunization program. *Vaccine*, 32(3):320–326.
- Pereira-Scalabrino, A., Almonte, M., and dos Santos-Silva, I. (2013). Country-level correlates of cervical cancer mortality in Latin America and the Caribbean. salud pública de méxico, 55(1):5–15.
- Rand, C. M., Brill, H., Albertin, C., Humiston, S. G., Schaffer, S., Shone, L. P., Blumkin, A. K., and Szilagyi, P. G. (2015). Effectiveness of centralized text message reminders on human papillomavirus immunization coverage for publicly insured adolescents. *Journal of Adolescent Health*, 56(5):S17–S20.
- Reynolds, D. and O'Connell, K. A. (2012). Testing a model for parental acceptance of human papillomavirus vaccine in 9-to 18-year-old girls: a theory-guided study. *Journal of pediatric nursing*, 27(6):614–625.

- Rosenthal, S. L., Rupp, R., Zimet, G. D., Meza, H. M., Loza, M. L., Short, M. B., and Succop, P. A. (2008). Uptake of HPV vaccine: demographics, sexual history and values, parenting style, and vaccine attitudes. *Journal of Adolescent Health*, 43(3):239–245.
- Rutten, L. (2023). Barriers to HPV Screening and Prevention in Latin America: A systematic Review.
- Sackey, M. E., Markey, K., and Grealish, A. (2022). Healthcare professional's promotional strategies in improving human papillomavirus (HPV) vaccination uptake in adolescents: A systematic review. Vaccine, 40(19):2656–2666.
- Sekine, M., Yamaguchi, M., Kudo, R., Hanley, S. J., Ueda, Y., Adachi, S., Kurosawa, M., Miyagi, E., Hara, M., and Enomoto, T. (2021). Suspension of proactive recommendations for HPV vaccination has led to a significant increase in HPV infection rates in young Japanese women: real-world data. *The Lancet Regional Health–Western Pacific*, 16.
- Shapiro, G. K. (2022). HPV vaccination: an underused strategy for the prevention of cancer. *Current Oncology*, 29(5):3780–3792.
- Shinkafi-Bagudu, Z. (2020). Global partnerships for HPV vaccine must look beyond national income. JCO Global Oncology, 6.
- Simms, K. T., Hanley, S. J., Smith, M. A., Keane, A., and Canfell, K. (2020). Impact of HPV vaccine hesitancy on cervical cancer in Japan: a modelling study. *The Lancet Public Health*, 5(4):e223–e234.
- Smulian, E. A., Mitchell, K. R., and Stokley, S. (2016). Interventions to increase HPV vaccination coverage: a systematic review. *Human vaccines & immunotherapeutics*, 12(6):1566– 1588.
- Sparkman, G. and Walton, G. M. (2017). Dynamic norms promote sustainable behavior, even if it is counternormative. *Psychological science*, 28(11):1663–1674.
- Srivastava, A. N., Misra, J. S., Srivastava, S., Das, B. C., and Gupta, S. (2018). Cervical cancer screening in rural India: Status & current concepts. *Indian Journal of Medical Research*, 148(6):687–696.
- Suppli, C. H., Hansen, N. D., Rasmussen, M., Valentiner-Branth, P., Krause, T. G., and Mølbak, K. (2018). Decline in hpv-vaccination uptake in denmark-the association between hpv-related media coverage and hpv-vaccination. *BMC public health*, 18:1–8.
- Tampi, M., Carrasco-Labra, A., O'Brien, K. K., Velandia-González, M., and Brignardello-Petersen, R. (2023). Systematic review on reducing missed opportunities for vaccinations in Latin America. *Revista Panamericana de Salud Pública*, 46:e65.
- Teoh, D. (2019). The power of social media for HPV vaccination-not fake news! American Society of Clinical Oncology Educational Book, 39:75–78.

- Torres-Roman, J. S., Ronceros-Cardenas, L., Valcarcel, B., Bazalar-Palacios, J., Ybaseta-Medina, J., Carioli, G., La Vecchia, C., and Alvarez, C. S. (2022). Cervical cancer mortality among young women in Latin America and the Caribbean: trend analysis from 1997 to 2030. BMC public health, 22(1):113.
- Tsu, V. D., LaMontagne, D. S., Atuhebwe, P., Bloem, P. N., and Ndiaye, C. (2021). National implementation of HPV vaccination programs in low-resource countries: Lessons, challenges, and future prospects. *Preventive medicine*, 144:106335.
- Tsutsui, Y., Benzion, U., and Shahrabani, S. (2012). Economic and behavioral factors in an individual's decision to take the influenza vaccination in japan. *The Journal of Socio-Economics*, 41(5):594–602.
- Urrutia, M.-T., Araya, A.-X., Gajardo, M., Chepo, M., Torres, R., and Schilling, A. (2023). Acceptability of HPV Vaccines: A Qualitative Systematic Review and Meta-Summary. *Vaccines*, 11(9):1486.
- Vallely, L. A., Roberts, S. A., Kitchener, H. C., and Brabin, L. (2008). Informing adolescents about human papillomavirus vaccination: What will parents allow? *Vaccine*, 26(18):2203– 2210.
- Waller, J., Marlow, L. A., and Wardle, J. (2006). Mothers' attitudes towards preventing cervical cancer through human papillomavirus vaccination: a qualitative study. *Cancer Epidemiology Biomarkers & Prevention*, 15(7):1257–1261.
- WHO (2015). Information, Education and Communication for cervical cancer prevention and control in African countries: Training guide.
- WHO (2017). Human papillomavirus (hpv). Available online at: https://www.who.int/ europe/news-room/fact-sheets/item/human-papillomavirus-(hpv) [Accessed on Jul 12, 2024].
- WHO (2019). Immunization stress-related responses. a manual for program managers and health professionals to prevent, identify and respond to stress-related responses following immunization.
- WHO (2023). Immunization coverage. Available online at: https://www.who.int/ news-room/fact-sheets/detail/immunization-coverage [Accessed on Jul 12, 2024].
- WHO (2024a). Cervical cancer. Available online at: https://www.who.int/news-room/fact-sheets/detail/cervical-cancer [Accessed on Jul 12, 2024].
- WHO (2024b). Human papillomavirus (hpv) vaccination coverage. Available online at: https://immunizationdata.who.int/global/wiise-detail-page/ human-papillomavirus-(hpv)-vaccination-coverage [Accessed on Jul 12, 2024].
- WHO and WB (2024). Behavioral Science Around the World Volume iii: Public Health.

- Winkler, J. L., Wittet, S., Bartolini, R. M., Creed-Kanashiro, H. M., Lazcano-Ponce, E., Lewis-Bell, K., Lewis, M. J., and Penny, M. E. (2008). Determinants of human papillomavirus vaccine acceptability in Latin America and the Caribbean. *Vaccine*, 26:L73–L79.
- Zimet, G. D., Shew, M. L., and Kahn, J. A. (2008). Appropriate use of cervical cancer vaccine. Annu. Rev. Med., 59(1):223–236.

Appendix

	С-Р	C - T ₁	C - T ₂	C - T ₃	C - T ₄	P - T ₁	P - T ₂	P - T ₃	P - T ₄	T ₁ - T ₂	T ₁ - T ₃	T ₁ - T ₄	T ₂ - T ₃	T_2 - T_4	T ₃ - T ₄
Subsidized	-0.000	0.000	-0.000	-0.000	-0.000	0.000	0.000	0.000	0.000	-0.000	-0.000	-0.000	0.000	-0.000	-0.000
	(0.009)	(0.009)	(0.009)	(0.009)	(0.009)	(0.009)	(0.009)	(0.009)	(0.010)	(0.009)	(0.009)	(0.009)	(0.009)	(0.009)	(0.009)
Age	-0.067	-0.026	-0.073	-0.091	-0.047	0.041	-0.006	-0.024	0.020	-0.047	-0.065	-0.021	-0.018	0.026	0.044
	(0.074)	(0.074)	(0.074)	(0.073)	(0.074)	(0.074)	(0.074)	(0.074)	(0.074)	(0.074)	(0.074)	(0.074)	(0.074)	(0.074)	(0.074)
17 years old	-0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	-0.000	-0.000
	(0.009)	(0.009)	(0.009)	(0.009)	(0.009)	(0.009)	(0.009)	(0.009)	(0.009)	(0.009)	(0.009)	(0.009)	(0.009)	(0.009)	(0.009)
Income															
Low income	-0.000	0.000	-0.000	-0.000	-0.000	0.000	0.000	0.000	0.000	-0.000	-0.000	-0.000	0.000	-0.000	-0.000
	(0.009)	(0.009)	(0.009)	(0.009)	(0.009)	(0.009)	(0.009)	(0.009)	(0.010)	(0.009)	(0.009)	(0.009)	(0.009)	(0.009)	(0.009)
Medium income	0.001	0.000	0.001	0.000	0.000	-0.001	0.000	-0.000	-0.000	0.001	0.000	0.000	-0.000	-0.000	0.000
	(0.014)	(0.014)	(0.014)	(0.014)	(0.014)	(0.014)	(0.014)	(0.014)	(0.014)	(0.014)	(0.014)	(0.014)	(0.014)	(0.014)	(0.014)
High income	-0.000	0.000	-0.000	-0.000	0.000	0.000	-0.000	0.000	0.000	-0.000	-0.000	0.000	0.000	0.000	0.000
	(0.012)	(0.012)	(0.012)	(0.012)	(0.012)	(0.012)	(0.012)	(0.012)	(0.012)	(0.012)	(0.012)	(0.012)	(0.012)	(0.012)	(0.012)
Dussiana dasa															
Previous doses															
At least one dose	0.002	0.005	0.011*	-0.000	0.006	0.003	0.009	-0.002	0.004	0.006	-0.006	0.001	-0.011*	-0.005	0.006
	(0.005)	(0.005)	(0.005)	(0.005)	(0.005)	(0.005)	(0.005)	(0.005)	(0.005)	(0.004)	(0.005)	(0.005)	(0.005)	(0.004)	(0.005)
Complete scheme	0.001	-0.001	-0.001	-0.002	0.000	-0.002	-0.002	-0.003	-0.001	-0.000	-0.001	0.001	-0.000	0.002	0.002
	(0.001)	(0.002)	(0.002)	(0.002)	(0.002)	(0.002)	(0.002)	(0.002)	(0.001)	(0.002)	(0.002)	(0.002)	(0.002)	(0.002)	(0.002)
Observations	5077	5078	5077	5077	5078	5077	5076	5076	5077	5077	5077	5078	5076	5077	5077

Table A1: Balance - Comparison Among Treatments

Notes: Previous doses indicates whether the girl has received any dose before the intervention. A complete scheme is conformed by two doses. C is the control group, P is the placebo group, T_1 is the Information SMS group, T_2 is the Social Norms SMS group, T_3 is the Trust SMS group and T_4 is the Framing SMS group. Standard errors in parentheses. *** p<0.001, ** p<0.01, * p<0.05

	Model 1	Model 2	
Treatment			
Placebo	0.003	0.004	
	(0.007)	(0.007)	
Information	0.023**	0.024***	
	(0.007)	(0.007)	
Social norms	0.020**	0.019**	
	(0.007)	(0.007)	
Trust	0.032***	0.033***	
	(0.007)	(0.007)	
Framing	0.023**	0.024^{***}	
	(0.007)	(0.007)	
Girl has received a previous dose	0.061^{*}	0.056	
-	(0.030)	(0.030)	
Treatment x Received a previous dose			
Placebo & Previous dose	-0.027	-0.026	
	(0.043)	(0.043)	
Information & Previous dose	0.134^{**}	0.130**	
	(0.045)	(0.045)	
Social norms & Previous dose	0.012	0.013	
	(0.049)	(0.049)	
Trust & Previous dose	-0.054	-0.056	
	(0.043)	(0.043)	
Framing & Previous dose	0.130^{**}	0.125^{**}	
	(0.045)	(0.045)	
Constant	0.056 ***	-0.044	
	(0.005)	(0.030)	
Strata fixed effects	No	Yes	
Covariates	No	Yes	
R-squared	0.007	0.033	
Observations	$15,\!178$	$15,\!178$	

Table A2: Effect on HPV Vaccine Uptake by Dose Received

Models 1 and 2 estimate the interaction between the treatment variable and whether the girl is receiving her first or second dose of the HPV vaccine. Since the HPV vaccination scheme consists of only two doses, a girl is considered to be receiving the second dose if she had already received one prior to the intervention; otherwise, it is her first dose. Model 2 includes as covariates whether a girl is under subsidized scheme, healthcare center visited, and the stratification variable which includes level of income and age. Standard errors in parentheses. *** p<0.001, ** p<0.01, * p<0.5

	Model 1	Model 2	
Treatment			
Placebo	0.004	0.004	
	(0.008)	(0.008)	
Information	0.027***	0.029***	
	(0.008)	(0.008)	
Social norms	0.020*	0.020*	
	(0.008)	(0.008)	
Trust	0.030***	0.031***	
	(0.008)	(0.008)	
Framing	0.025**	0.026**	
-	(0.008)	(0.008)	
Girl is 17 years old	-0.037*	-0.037*	
v	(0.017)	(0.016)	
Treatment x At the age limit for friction	ree vac-	× ,	
Placebo & 17 years old	-0.015	-0.010	
	(0.024)	(0.023)	
Information & 17 years old	-0.013	-0.014	
-	(0.024)	(0.023)	
Social norms & 17 years old	-0.006	-0.004	
	(0.024)	(0.023)	
Trust & 17 years old	0.002	0.004	
	(0.024)	(0.023)	
Framing & 17 years old	0.006	0.009	
	(0.024)	(0.023)	
Constant	0.062 ***	-0.026	
	(0.006)	(0.029)	
Strata fixed effects	No	Yes	
Covariates	No	Yes	
R-squared	0.005	0.031	
Observations	$15,\!178$	$15,\!178$	

Table A3: Effect on HPV Vaccine Uptake by Age

Models 1 and 2 estimate the interaction between the treatment variable and whether the girl is under or exactly 17 years old (which is the age limit to receive free HPV vaccination). Model 2 includes as covariates whether a girl is under subsidized scheme, whether she has received a dose before, healthcare center visited and household income level. Standard errors in parentheses. *** p < 0.001, ** p < 0.01, * p < 0.5

	Model 1	Model 2
Treatment		
Placebo	0.021	0.020
	(0.020)	(0.020)
Information	0.012	0.016
	(0.020)	(0.020)
Social norms	0.012	0.010
	(0.020)	(0.020)
Trust	0.030	0.025
	(0.020)	(0.020)
Framing	0.009	0.009
-	(0.020)	(0.020)
Household income level		
Medium	0.035^{*}	0.030
	(0.016)	(0.016)
High	0.035**	0.030
-	(0.018)	(0.016)
Treatment x Household income level		
Placebo & Middle income	-0.018	-0.016
	(0.022)	(0.022)
Information & Middle income	0.015	0.013
	(0.022)	(0.022)
Social norms & Middle income	0.012	0.014
	(0.022)	(0.022)
Trust & Middle income	0.006	0.014
	(0.022)	(0.022)
Framing & Middle income	0.017	0.018
	(0.022)	(0.022)
Placebo & High income	-0.030	-0.029
0	(0.025)	(0.025)
Information & High income	0.018	0.015
	(0.025)	(0.025)
Social norms & High income	0.001	0.002
0	(0.025)	(0.025)
Trust & High income	-0.015	-0.008
0	(0.025)	(0.025)
Framing & High income	0.026	0.027
	(0.025)	(0.025)
Constant	0.024	-0.041
	(0.014)	(0.030)
Strata fixed effects	No	Yes
Covariates	No	Yes
R-squared	0.006	0.031
Observations	15.178	15,178

Table A4: Effect on HPV Vaccine Uptake by Income Level

Models 1 and 2 estimate the interaction between the treatment variable and the household income level that the girl belongs to. Model 2 includes as covariates whether a girl has received a dose before, healthcare center visited and age. Standard errors in parentheses. *** p < 0.001, ** p < 0.01, * p < 0.5

Table A5: Content of Messages (Spanish)

Treatment	Message 1	Message 2	Message 3	Message 4	Message 5	Message 6	Message 7	Message 8
Control	No message	No message	No message	No message	No message	No message	No message	No message
Placebo	Hola mamá de , te	Hola mamá de , juntos	Hola mamá de , la salud	Hola mamá de , cuida tu	Hola mamá de , contamos	Hola mamá de , felices fi-	Hola mamá de , feliz año	Hola mamá de , feliz año
	brindamos todo	por un Cali salud-	es lo más impor-	salud.	con los servicios	estas. Cuida tu salud.	nuevo. Sigue los	nuevo. Mantente
	lo que tu familia	able.	tante en la vida.		de salud que tu		lineamientos de	saludable en este
	necesita.				familia necesita.		salud este nuevo	nuevo año.
							año.	
	Secretaría de Salud	Secretaría de Salud	Secretaría de Salud	Secretaría de Salud	Secretaría de Salud	Secretaría de Salud	Secretaría de Salud	Secretaría de Salud
	Hola mamá de	Hola mamá de	Hola mamá de	Hola mamá de	Hola mamá de	Hola mamá de	Hola mamá de	Hola mamá de
Information	, sabías	, recuerda	, hay 150	, la vac-	, vacuna a	, haz click	, tu hija	, recuerda
	que la vacuna	que las niñas de	centros de vacu-	unación contra el	tu hija contra el	aquí y ubica los sitios	de 9-17 años	que a tu hija aún
	contra el VPH es	9-17 años deben	nación públicos	VPH reduce 89%	VPH.	de vacunación con-	tiene derecho s	le falta la vacuna
	gratuita en Cali	vacunarse contra	en Cali en donde	el riesgo de cáncer		tra el VPH en Cali:	vacunarse gra-	contra el VPH.
	para las niñas de	el VPH.	puedes vacunar a	cervical.		https://bit.ly/ ssalud-	tuitamente contra	
	9-17?		tu hija contra el VPH			cali. Vacuna a tu hija.	el VPH.	
	Secretaría de Salud	Secretaría de Salud	Secretaría de Salud	Secretaría de Salud	Secretaría de Salud	Secretaría de Salud	Secretaría de Salud	Secretaría de Salud
a . 1 M	Hola mamá de	Hola mamá de	Hola mamá de	Hola mamá de	Hola mamá de	Hola mamá de	Hola mamá de	Hola mamá de
Social Norms	, 3 de 10	, recuerda	, en Cali	, la va-	, 3 de 10	, haz click	,3 de 10	, recuerda
	padres en Cali con	que las ninas de	3 de 10 padres	cunación contra	padres en Cali con	aqui y ubica los sitios	padres de ninas	que a tu hija aun
	ninas de edad de	9-17 deben vac-	de ninas como tu	el VPH reduce	ninas de edad de	de vacunación con-	de 9-17 anos ya	contra ol VPH
	naron a su hija	VPH y la vacuna	vacunado contra el	cáncer cervical	vacunado contra el	https://bit.lv/_ssalud-	contra el VPH	La vacunación es
	contra el VPH	es gratuita para	VPH v cada vez se	Vacúnala en uno	VPH up alza del	cali Vacuna a tu hija	un alza del 149%	gratis para las
	Todavía faltas tú	esas edades.	suman más.	de los 150 centros	149% desde 2016.	can. vacuna a tu mja.	desde 2016. To-	niñas de 9-17.
	:(de vacunación.			davía faltas tú :(
	Secretaría de Salud	Secretaría de Salud	Secretaría de Salud	Secretaría de Salud	Secretaría de Salud	Secretaría de Salud	Secretaría de Salud	Secretaría de Salud
	Hola mamá de	Hola mamá de	Hola mamá de	Hola mamá de	Hola mamá de	Hola mamá de	Hola mamá de	Hola mamá de
Trust	, los	, recuerda	, la Sec-	, la va-	, Cali re-	, haz click	, los	, recuerda
	médicos especial-	que las niñas de	retaría de Salud	cunación contra	comienda y pone a	aquí y ubica los sitios	médicos y la Sec-	que a tu hija aún
	istas recomiendan	9-17 deben vac-	en Cali recomieda	el VPH reduce	disposición la vac-	de vacunación con-	retaría de Salud	le falta la vacuna
	la vacunación de	unarse contra el	la vacunación de	89% el riesgo de	una del VPH para	tra el VPH en Cali:	firmemente re-	contra el VPH.
	tu hija contra el	VPH y la vacuna	tu hija contra el	cáncer cervical.	el bienestar de tu	https://bit.ly/ ssalud-	comiendan la	La vacunación es
	VPH.	es gratuita para	VPH.	Vacunala en uno	hija en 150 centros	cali. Vacuna a tu hija.	vacunación contra	gratis para las
		esas edades.		de los 150 centros	de vacunación.		el VFH de tu fija	ninas de 9-17.
				de vacunación.			años	
	Secretaría de Salud	Secretaría de Salud	Secretaría de Salud	Secretaría de Salud	Secretaría de Salud	Secretaría de Salud	Secretaría de Salud	Secretaría de Salud
	Hola mamá de	Hola mamá de	Hola mamá de	Hola mamá de	Hola mamá de	Hola mamá de	Hola mamá de	Hola mamá de
Framing	, tu hija	, recuerda	, Sabes	, la va-	, tienes	, haz click	, en el	, recuerda
	debe tener puestas	que las niñas de	que la vacuna	cunación contra	una cita el 00 de	aquí y ubica los sitios	2020, 4,742 mu-	que a tu hija aún
	las 21 vacunas	9-17 deben vac-	contra el VPH es	el VPH reduce	MES a la HORA	de vacunación con-	jeres desarrollaron	le falta la vacuna
	en su carnet de	unarse contra el	tan segura como	89% el riesgo de	am para vacunar	tra el VPH en Cali:	cancer cervical	contra el VPH.
	vacunación y aún	VPH y la vacuna	otras vacunas?	cancer cervical.	a tu hija contra	nttps://bit.ly/ ssalud-	en Cali. Evita	La vacunacion es
	contra al VPH	es gratuita para		de los 150 contros	er vrin. nay una	can. vacuna a tu IIIja.	vacuna do VPH on	piñas do 0.17
	contra ci vi ii.	coas cuauco.		de vacunación.	para ella.		niñas de 9-17.	mnab ut 3-17.
	Secretaría de Salud	Secretaría de Salud	Secretaría de Salud	Secretaría de Salud	Secretaría de Salud	Secretaría de Salud	Secretaría de Salud	Secretaría de Salud

Table A6: Content of Messages (English)

Treatment	Message 1	Message 2	Message 3	Message 4	Message 5	Message 6	Message 7	Message 8
Control	No message	No message	No message	No message	No message	No message	No message	No message
	Hello's	Hello's	Hello's	Hello's	Hello's	Hello's mom,	Hello's	Hello's
Placebo	mom, we offer you	mom, together for	mom, health is the	mom, take care of	mom, we have the	Happy Holidays. Take	mom, Happy New	mom, Happy New
	everything your	a healthy Cali.	most important	your health.	health services	care of your health.	Year. Follow the	Year. Stay healthy
	family needs.		thing in life.		your family needs.		health guidelines	this new year.
							this new year.	
	Constanist of	Samataniat of	Samataniat of	Samutaniat of	Samataniat of	Connectoriat of Haalth	Constanist of	Constanist of
	Health	Health	Health	Health	Health 01	Secretariat of Health	Health	Health OI
	Hello 's	Hello 's	Hello 's	Hello 's	Hello 's	Hello 's mom	Hello 's	Hello 's
Information	mom, did vou	mom, remember	mom, there are	mom. the HPV	mom, vaccinate	click here to find	mom, your daugh-	mom, remember
	know that the	that girls aged	150 public vacci-	vaccine reduces	vour daughter	the HPV vaccina-	ter aged 9-17 has	that your daughter
	HPV vaccine is	9-17 should get	nation centers in	the risk of cervical	against HPV.	tion centers in Cali:	the right to get	still needs the
	free in Cali for	vaccinated against	Cali where you	cancer by 89%.	0	https://bit.ly/ssaludcali.	vaccinated against	HPV vaccine.
	girls aged 9-17?	HPV.	can vaccinate your			Vaccinate your daugh-	HPV for free.	
			daughter against			ter.		
			HPV.					
	Secretariat of	Secretariat of	Secretariat of	Secretariat of	Secretariat of	Secretariat of Health	Secretariat of	Secretariat of
	Health Health	Health	Health Health	Health Hello	Health Health	II-lla la man	Health	Health
Social Norms	mom 3 out of 10	mom remember	mom in Cali 3	mom the HPV	mom 3 out of 10	click here to find	mom 3 out of 10	mom remember
boeiar riorins	parents in Cali	that girls aged	out of 10 parents	vaccine reduces	parents in Cali	the HPV vaccina-	parents of girls	that your daughter
	with daughters of	9-17 should get	of girls like your	the risk of cervical	with daughters	tion centers in Cali:	aged 9-17 have	still needs the
	vour daughter's	vaccinated against	daughter have	cancer by 89%.	of your daugh-	https://bit.lv/ssaludcali.	already vaccinated	HPV vaccine. Vac-
	age have already	HPV and the	already vaccinated	Vaccinate her at	ter's age have	Vaccinate your daugh-	them against HPV,	cination is free for
	vaccinated their	vaccine is free for	them against HPV	one of the 150 vac-	vaccinated them	ter.	a 149% increase	girls aged 9-17.
	daughters against	those ages.	and more are join-	cination centers.	against HPV, a		since 2016. You're	
	HPV. You're still		ing every day.		149% increase		still missing :(
	missing :(since 2016.			
	Secretariat of	Secretariat of	Secretariat of	Secretariat of	Secretariat of	Secretariat of Health	Secretariat of	Secretariat of
	Health	Health	Health	Health	Health	II. 11	Health	Health
Trust	Hellos	Hellos	Hello's	HelloS	Hellos	aliak here to find	Hellos	Hellos
11030	doctors recom	that girls aged	tary of Health in	wassing reduces	ommonds and	the HPV vaccine	the Secretary of	that your daughter
	mend vaccinating	9-17 should get	Cali recommends	the risk of cervical	provides the HPV	tion centers in Cali:	Health strongly	still needs the
	vour daughter	vaccinated against	vaccinating your	cancer by 89%.	vaccine for the	https://bit.lv/ssaludcali.	recommend vac-	HPV vaccine. Vac-
	against HPV.	HPV and the	daughter against	Vaccinate her at	well-being of your	Vaccinate your daugh-	cinating your	cination is free for
	0	vaccine is free for	HPV.	one of the 150 vac-	daughter at 150	ter.	daughter and girls	girls aged 9-17.
		those ages.		cination centers.	vaccination cen-		aged 9-17 against	
					ters.		HPV.	
	Construction of the	Constant of C	G.,	G	G		G	G.,
	Secretariat of	Secretariat of	Secretariat of	Secretariat of	Secretariat of	Secretariat of Health	Secretariat of	Secretariat of
	Hello 'e	Hello 's	Hello 's	Hello 's	Hello 's	Hello 's mom	Hello 's	Hello 's
Framing	mom your daugh-	mom remember	mom did you	mom the HPV	mom vou have	click here to find	mom in 2020	mom remember
1.000008	ter should have	that girls aged	know that the	vaccine reduces	an appointment	the HPV vaccina-	4.742 women de-	that your daughter
	all 21 vaccines in	9-17 should get	HPV vaccine is	the risk of cervical	on the 00th of	tion centers in Cali:	veloped cervical	still needs the
	her vaccination	vaccinated against	as safe as other	cancer by 89%.	MONTH at TIME	https://bit.ly/ssaludcali.	cancer in Cali.	HPV vaccine. Vac-
	card and she's still	HPV and the	vaccines?	Vaccinate her at	am to vaccinate	Vaccinate your daugh-	Prevent cancer	cination is free for
	missing the HPV	vaccine is free for		one of the 150 vac-	your daughter	ter.	with the HPV	girls aged 9-17.
	vaccine.	those ages.		cination centers.	against HPV.		vaccine for girls	
					There's a vaccine		aged 9-17.	
	a	a	a	a	reserved for her.		a	a
	Secretariat of	Secretariat of	Secretariat of	Secretariat of	Secretariat of	Secretariat of Health	Secretariat of	Secretariat of
	Health	nealth	nealth	Health	nealth		Health	nealth



Figure A1: Effect on HPV Vaccination by Age



Figure A2: Effect on HPV Vaccination by Income Level

Notes: The figure shows the predicted mean vaccination rates by treatment and household income level It includes 95% confidence interval. Estimates are based on a linear regression model incorporating an interaction term for treatment and household income level, along with covariates such as whether a girl has received a dose before, healthcare center visited and girl's age.